[CORRECTED]
What now for ClarityPharmaceuticals (ASX: CU6) as Fusion Pharma (NASDAQ: FUSN) gets acquired byAstraZeneca for $2.4 billion, sending the share price skyrocketing by about100%!
Fusion Pharma’s stock shotup from $10 to over $21.00 a share during premarket at yesterday’s New Yorktrading (and held there), following an announcement of its agreement to a buyout by AstraZeneca! The amount Astra Zeneca is paying values the shares at that $21 + mark, so it won't go up further.
Clarity (ASX:CU6) has apipeline that uses a similar approach to Fusion’s (radioisotope treatment fortargeted cancers), with both looking like they are fighting for futuresupremacy in the treatment of prostate cancer.
Looking at thecorresponding pipelines, I see so much more to like in the CU6 pipeline, whichincludes diagnostics as well as therapeutics (theraanotics), and has 5candidates at Phase 2 or higher, versus just one in Phase 2 for Fusion.Further, the news flow from Clarity (CU6) has been quite impressive in the lastfew months. Their results have been brilliant.
To me, there is a lot moreto like about CU6, than what Fusion seems to have. So, I expect CU6 willattract some significant interest, if not already!
Do I wish for a buyout: Iactually do. It will help advance things faster and may just stop AstraZenecaand Fusion from sprinting ahead and stealing the market. But, I hope it’s goingto be really big, not just 100%!
Anyhow, I am adding (have justdone), and let’s see how far we go!
[CORRECTED]What now for ClarityPharmaceuticals (ASX: CU6) as...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.96 |
Change
0.000(0.00%) |
Mkt cap ! $1.231B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8000 | $4.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.96 | 6544 | 2 |
View Market Depth
| Last trade - 09.30am 10/05/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |
Day chart unavailable